GoodRx reports transitioning from injectable to oral GLP-1s can simplify weight loss routines, but requires careful timing and consistency.

The government plans to introduce lenacapavir, a long-acting injectable drug for HIV prevention, in the last quarter of the year, according to Rwanda Biomedical Centre (RBC).

The company's recent momentum was further solidified by a successful $500k funding, a strategic injection of capital that has fueled the transition from R&D to high-scale manufacturing. As HoverIt ...

Eli Lilly has further expanded its weight-loss initiatives with novel therapies such as orforglipron, an oral GLP-1 receptor ...

Moorfields hospital in London is the world's first dedicated clinic for the disorder and seven out of eight patients given ...

Once remote control is established on an endpoint, adversarial AI reportedly adjusts the malicious process’s activities in ...

Analysts predict that the new assistant will gain traction in knowledge-driven roles, particularly in environments where ...

Quite a few people have sent me a report seemingly commissioned by the GoldBod and written by three economists, some with ...

To govern is to choose, and Labour is choosing to run away from the electorate at every turn. As reported by The Telegraph, ...

Eli Lilly (LLY) says its weight-loss pill is on track to be approved in the US, lagging behind Novo Nordisk (NVO). Eli Lilly ...

Last year, the US authorities approved the first at-home test that can detect three common infections in women — gonorrhea, ...

Security researchers from Radware have demonstrated techniques to exploit ChatGPT connections to third-party apps to turn ...